US pharma giant Pfizer (NYSE: PFE) has named the executive leadership team that will take up the reins after its acquisition of Irish-based Allergan (NYSE: AGN) is finalised at the end of this year.
Viagra maker Pfizer agreed at the end of November 2015 to acquire Botox manufacturer Allergan for $160 billion in a controversial tax inversion deal.
In a statement published yesterday (February 8), the drugmaker said it will continue to manage its commercial operations through two distinct businesses – the innovative products business and the established products business – after the completion of the proposed transaction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze